The OBR (Office for Budget Responsibility) anticipates economic output in Britain to expand by 1.8% in 2026 and by 1.5% in ...
Daiichi Sankyo has signed a deal worth up to $300 million with South Korean biotech Alteogen to develop a subcutaneous ...
Shares of AstraZeneca dropped more than 7% yesterday after the Chinese publication Yicai Global reported that dozens of ...
Zacks.com on MSN4d
Buy, Sell, or Hold AstraZeneca Stock? Key Tips Ahead of Q3 EarningsKey Takeaways Zacks earnings estimates for AstraZeneca are currently at $4.06 per share. However, the earnings picture ...
Sarepta will discontinue its next generation of exon-skipping drugs for Duchenne muscular dystrophy over safety concerns, in ...
Two current and two former senior AstraZeneca Plc executives in the group’s China unit are under investigation in a probe into alleged breaches of laws around drug importation and data privacy, the ...
Greetings and welcome to I US third quarter, 2024 earnings conference call. (Operators Instructions). I would now like to turn the conference over to your host, Jordan Shapiro. Thank you. You may ...
AbbVie is reaching for the Sky(rizi) as it spent a staggering $51.5 million on TV drug ads for its immunology blockbuster in October. | AbbVie is reaching for the Sky(rizi) as it spent a staggering ...
These are still high on the list of AZ’s core focus today ... to have paid off – between 2005 and 2010 AstraZeneca‘s success rates for taking drugs from candidate nomination to phase ...
Powerful weight-loss drugs like Wegovy and Zepbound have driven nearly $1 trillion in market-capitalization gains, with most ...
DoP rejects Aristo Pharma’s review application for its multivitamin tablets: Gireesh Babu, New Delhi Friday, November 8, 2024, 08:00 Hrs [IST] The Department of Pharmaceuticals ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback